Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery

Diabetes, Obesity and Metabolism

Volumn 8, Issue 2, 2006, Pages 119-124

  Baker, Andrew H ^a   Yim, Anthony P C ^b   Wan, Song ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adenovirus; Bypass grafting; Gene therapy; Neointima; Vascular disease

Indexed keywords

ADENOVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NEURONAL NITRIC OXIDE SYNTHASE; OLIGONUCLEOTIDE; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DNA MODIFICATION; EX VIVO STUDY; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GRAFT FAILURE; HUMAN; INTIMA; REVIEW; SAPHENOUS VEIN; TRANSGENE; VASCULAR DISEASE; VASCULAR PATENCY; VEIN GRAFT; VIRAL GENE DELIVERY SYSTEM;

EID: 33645975489     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1007/1-4020-4107-1_9     Document Type: Review

References (38)

1. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA guidelines for coronary artery bypass graft surgery: Report of the American college of cardiology/American heart association task force on practice guidelines (committee to revise the 1991 guidelines on coronary artery bypass graft surgery). J Am Coll Cardiol 1999; 34: 1262-1342.
2. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45-68.
3. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 1994; 9: 641-649.
4. Davies MG, Hagen P-O. Pathobiology of intimal hyperplasia: A review. Eur J Vasc Surg 1995; 9: 7-18.
5. Graham MM, Ghali WA, Faris PD, Galbraith D, Norris CM, Knudtson ML. Survival after coronary revascularization in the elderly. Circulation 2002; 105: 2378-2384.
6. Barzilay JI, Kronmal RA, Bittner V. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged >65 years. Am J Cardiol 1994; 24: 334-339.
7. Brener S, Lytle B, Casserly I, Schneider J, Topol E, Lauer M. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004; 109: 2290-2295.
8. de Feyter PJ, van Suylen RJ, de Jaegere PP. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993; 21: 1539-1549.
9. Keeley E, Velez C, O'Neill W. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001; 38: 659-665.
10. Piana RN, Moscucci M, Cohen DJ. Palmaz-Schatz stenting for treatment of focal vein graft stenosis: Immediate results and long-term outcome. J Am Coll Cardiol 1994; 23: 1296-1304.
11. Al Suwaidi J, Velianou JL, Berger PB. Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. Am Heart J 2001; 142: 452-459.
12. Singh M, Rosenschein U, Ho K, Berger P, Kuntz R, Holmes D. Treatment of saphenous vein bypass grafts with ultrasound thrombolysis. Circulaton 2003; 107: 2331-2336.
13. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
14. Tomko RP, Xu R, Philipson L. HCAR and MCAR. The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
15. 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
16. George S, Johnson J, Angelini G, Newby A, Baker A. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-877.
17. George S, Lloyd C, Angelini G, Newby A, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
18. Channon KM, Fulton GJ, Gray JL et al. Efficient adenoviral gene transfer to early venous bypass grafts: Comparison with native vessels. Cardiovasc Res 1997; 35 (3): 505-513.
19. Nicklin S, Von Seggern D, Work L et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
20. Newman KD, Dunn PF, Owens JW et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955-2965.
21. Wen S, Schneider DB, Driscoll RM, Vassalli G, Sassani AB, Dichek DA. Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler Thromb Vasc Biol 2000; 20: 1452-1458.
22. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004; 110: 1484-1491.
23. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72 (12): 9873-9880.
24. Nakai H, Montini E, Fuess S, Storm T, Grompe M, Kay M. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003; 34: 297-302.
25. George S, Baker A, Angelini G, Newby A. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metelloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998; 5: 1552-1560.
26. Bond M, Murphy G, Bennett MR, Amour A, Knauper V, Newby AC. Localisation of the death domain of TIMP-3 to the N-terminus: Metalloproteinase inhibition is associated with pro-apoptotic activity. J Biol Chem 2000; 275: 41358-41363.
27. Bond M, Murphy G, Bennett M, Newby A, Baker A. Tissue inhibitor of metalloproteinase-3 induces a fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002; 277: 13787-13795.
28. Cheng L, Mantile G, Pauly R et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998; 98 (20): 2195-2201.
29. Bendeck MP, Irvin C, Reidy MC. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78: 38-43.
30. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996; 16: 28-33.
31. West NEJ, Qian H, Guzik TJ et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: Effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001; 104 (13): 1526-1532.
32. Mann MJ, Whittemore AD, Donaldson MC et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
33. Mann M, Gibbons G, Kernoff R et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995; 92 (10): 4502-4506.
34. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106 (9): 1071-1075.
35. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 4: 714-722.
36. Mann MJ, Gibbons GH, Tsao PS et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997; 99 (6): 1295-1301.
37. George SJ, Capogrossi MC, Angelini GD, Baker AH. Wild type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 2001; 8: 668-676.
38. Wan S, George SJ, Nicklin SA, Yim APC, Baker AH. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004; 9: 689-698.